Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis
Abstract
Aims Sodium-glucose cotransporter 2 (SGLT2) inhibitors are currently FDA approved for the management of type 2 diabetes. Our objective was to review the available evidence of the effects of SGLT2 inhibitors on HbA 1c, body weight, and total daily insulin dose, as well as their safety profile in patients with type 1 diabetes.Methods Four randomized controlled trials (RCTs) were identified by conducting a systematic search of PubMed, Embase, Web of Science, Scopus and Cochrane library databases through August 2017. Data on study design, sample size, mean ± standard deviation of HbA 1c, body weight, and total daily insulin dose, as well as reported adverse events were extracted. Weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated using a random-effects model.Results Relative to placebo, therapy with SGLT2 inhibitors led to significant reductions in HbA 1c (WMD 0.39; 95% CI 0.27, 0.51), body weight (WMD 2.76; 95% CI 1.11, 4.40), and total daily insulin dose (WMD 5.03; 95% CI 1.83, 8.23). In addition, there was no significant difference in the rate of adverse events.Conclusions The current study lends supports for the development of SGLT2 inhibitors in combination with insulin as a treatment option for patients with type 1 diabetes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A 2018 meta-analysis suggests SGLT2 inhibitors are safe in type 1 diabetes.
“A 2018 meta-analysis of these inhibitors suggests they are safe,87”
From Type 1 diabetes (2018) · cites this paper as [87]
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042 · see citing works
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859 · see citing works
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667 · see citing works
A Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569 · cited 1× · see citing works
“accounting for between study variation was adopted regardless of I 2 [43].”
MethodPrevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412 · see citing works
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · see citing works
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · see citing works
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 976 · see citing works
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867 · see citing works
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 776 · see citing works
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712 · see citing works
Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010
Livingstone, S. J., Levin, D., Looker, H. C., Lindsay, R. S., Wild, S. H., Joss, N., Leese, G., Leslie, P., McCrimmon, R. J., Metcalfe, W., et al. (2015) · JAMA · doi:10.1001/jama.2014.16425 · Cited by 621 · see citing works
SGLT2 Inhibitors May Predispose to Ketoacidosis
Taylor, S. I., Blau, J. E., & Rother, K. I. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1884 · Cited by 561 · see citing works
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D. A. H., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 496 · see citing works
Projections of Type 1 and Type 2 Diabetes Burden in the U.S. Population Aged <20 Years Through 2050
Imperatore, G., Boyle, J. P., Thompson, T. J., Case, D., Dabelea, D., Hamman, R. F., Lawrence, J. M., Liese, A. D., Liu, L. L., Mayer‐Davis, E. J., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0669 · Cited by 485 · see citing works
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470 · see citing works
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 459 · see citing works
Baker, W. L., Smyth, L. R., Riche, D. M., Bourret, E. M., Chamberlin, K. W., & White, W. B. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.01.007 · Cited by 452 · see citing works
Oelze, M. W., Kröller‐Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293 · see citing works
Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M. (2015) · Diabetes Care · doi:10.2337/dc15-1730 · Cited by 286 · see citing works
Monami, M., Nardini, C., & Mannucci, E. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12244 · Cited by 284 · see citing works
Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Menezes, H. T., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 232 · see citing works
7. Approaches to Glycemic Treatment
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225 · see citing works
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Liakos, A., Karagiannis, T., Athanasiadou, E. A., Sarigianni, M., Mainou, M., Papatheodorou, K., Bekiari, E., & Τσάπας, Α. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12307 · Cited by 218 · see citing works
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Sands, A., Zambrowicz, B., Rosenstock, J., Lapuerta, P., Bode, B. W., Garg, S. K., Buse, J. B., Banks, P. L., Heptulla, R. A., Rendell, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2806 · Cited by 216 · see citing works
Libman, I. M., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Katz, M. L., Shah, A., Simmons, J. H., Haller, M. J., Raman, S., Tamborlane, W. V., et al. (2015) · JAMA · doi:10.1001/jama.2015.16174 · Cited by 181 · see citing works
Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12494 · Cited by 167 · see citing works
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.02.003 · Cited by 148 · see citing works
Yang, X., Lai, D., Zhong, X., Shen, H., & Huang, Y. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1730-x · Cited by 124 · see citing works
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Madaan, T., Akhtar, M., & Najmi, A. K. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.025 · Cited by 106 · see citing works
Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 103 · see citing works
Garg, S. K., Moser, E. G., Bode, B. W., Klaff, L. J., Hiatt, W. R., Beatson, C. R., & Snell‐Bergeon, J. K. (2012) · Endocrine Practice · doi:10.4158/ep12100.or · Cited by 98 · see citing works
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
Frandsen, C. S., Dejgaard, T. F., & Madsbad, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00039-5 · Cited by 95 · see citing works
Rodbard, H. W., Peters, A. L., Slee, A., Cao, A., Traina, S. B., & Alba, M. (2017) · Diabetes Care · doi:10.2337/dc16-1353 · Cited by 94 · see citing works
Chen, J., Fan, F., Wang, J. Y., Long, Y., Gao, C., Stanton, R. C., & Xu, Y. (2017) · Scientific Reports · doi:10.1038/srep44128 · Cited by 91 · see citing works
Hatanaka, T., Ogawa, D., Tachibana, H., Eguchi, J., Inoue, T., Yamada, H., Takei, K., Makino, H., & Wada, J. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.239 · Cited by 91 · see citing works
Cheng, S. T. W., Chen, L., Li, S. Y. T., Mayoux, E., & Leung, P. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147391 · Cited by 83 · see citing works
Efficacy and Safety of Metformin for Patients with Type 1 Diabetes Mellitus: A Meta-Analysis
Liu, C., Wu, D., Zheng, X., Li, P., & Li, L. (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0190 · Cited by 78 · see citing works
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 76 · see citing works
Edelman, S. V., & Weyer, C. (2002) · Diabetes Technology & Therapeutics · doi:10.1089/15209150260007390 · Cited by 74 · see citing works
Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes
Kuhadiya, N. D., Ghanim, H., Mehta, A., Garg, M., Khan, S., Hejna, J., Torre, B., Makdissi, A., Chaudhuri, A., Batra, M., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1451 · Cited by 71 · see citing works
Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps
on behalf of the Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON), Driscoll, K. A., Corbin, K. D., Maahs, D. M., Pratley, R. E., Bishop, F. K., Kahkoska, A. R., Hood, K. K., & Mayer‐Davis, E. J. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0892-1 · Cited by 66 · see citing works
Potential role of non‐insulin adjunct therapy in Type 1 diabetes
George, P., & McCrimmon, R. J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03744.x · Cited by 49 · see citing works
Tamez, H. E., Tamez, A. L., Garza‐Garza, L. A., Hernandez, M. I., & Polanco, A. C. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0210-x · Cited by 34 · see citing works
Perkins, B. A., Cherney, D. Z. I., Soleymanlou, N., Lee, J. A., Partridge, H., Menezes, H. T., Zinman, B., Mazze, R., Fagan, N. M., Kaspers, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141085 · Cited by 32 · see citing works
Argento, N. B., & Nakamura, K. (2015) · Endocrine Practice · doi:10.4158/ep151016.or · Cited by 23 · see citing works
Yang, Y., Pan, H., Wang, B., Chen, S., & Zhu, H. (2017) · Chinese Medical Sciences Journal · doi:10.24920/j1001-9242.2007.003 · Cited by 22 · see citing works
Effect of Pioglitazone on the Course of New-Onset Type 1 Diabetes Mellitus
Sue, T. K., Godil, M. A., Harry, L. A., & Allen, W. T. (2013) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.981 · Cited by 20 · see citing works
Chen, M., Xie, C., Gao, H., Zheng, H., Chen, Q., & Fang, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010252 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561 · see citing works
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262 · see citing works
Jigheh, Z. A., Haghjo, A. G., Argani, H., Roshangar, L., Rashtchizadeh, N., Sanajou, D., Ahmad, S. N. S., Rashedi, J., Dastmalchi, S., & Abbasi, M. M. (2019) · PubMed Central · doi:10.22038/ijbms.2019.31788.7651 · Cited by 90 · see citing works
SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort
Ata, F., Yousaf, Z., Khan, A. A., Razok, A., Akram, J., Ali, E. A. H., Abdalhadi, A., Ibrahim, D. A., Al Mohanadi, D. H. S. H., & Danjuma, M. I. (2021) · Scientific Reports · doi:10.1038/s41598-021-89752-w · Cited by 87 · see citing works
Zheng, H., Liu, M., Li, S., Shi, Q., Zhang, S., Zhou, Y., & Su, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.706914 · Cited by 60 · see citing works
Ji, L., Liu, Y., Miao, H., Xie, Y., Yang, M., Wang, W., Mu, Y., Yan, P., Pan, S. M., Lauring, B. P., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13681 · Cited by 54 · see citing works
Lu, J.-L., Tang, L.-J., Meng, H.-Y., Zhao, J.-J., & Liang, Y. (2019) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.3169 · Cited by 37 · see citing works
Ciężki, S., Kurpiewska, E., Bossowski, A. T., & Głowińska‐Olszewska, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.890833 · Cited by 44 · see citing works
Karamanakos, G., Kokkinos, A. D., Dalamaga, Μ., & Liatis, S. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00477-x · Cited by 43 · see citing works
Li, K., & Xu, G. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12890 · Cited by 33 · see citing works
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35 · see citing works
Perez‐Nieves, M., Boye, K. S., Kiljanski, J. I., Cao, D., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0421-5 · Cited by 30 · see citing works
Rao, L., Ren, C., Luo, S., Huang, C., & Li, X. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01686-x · Cited by 29 · see citing works
Tandon, S., Ayis, S. A., Hopkins, D. L., Harding, S., & Stadler, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14221 · Cited by 24 · see citing works
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Perkins, B. A., Rosenstock, J., Skyler, J. S., Laffel, L. M., Cherney, D. Z. I., Mathieu, C., Pang, C., Wood, R., Kinduryte, O., George, J. T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0548 · Cited by 23 · see citing works
Elian, V., Popovici, V., Karampelas, O., Pîrcălăbioru, G. G., Radulian, G., & Muşat, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041972 · Cited by 25 · see citing works
Huang, Y., Jiang, Z., & Wei, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9813 · Cited by 21 · see citing works
Sabaner, M. C., Duman, R., Doğan, M., Akdoğan, M., Vurmaz, A., Bozkurt, E., & Beysel, S. (2021) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2021.01.005 · Cited by 21 · see citing works
Rodbard, H. W., Giaccari, A., Lajara, R., Stewart, J. A., Strumph, P., Oliveira, J. H., Lapuerta, P., & Castro, R. D. C. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14127 · Cited by 19 · see citing works
Zou, H., Liu, L., Guo, J., Wang, H., Liu, S., Xing, Y., Deng, C., Xiao, Y., & Zhou, Z. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13387 · Cited by 20 · see citing works
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 15 · see citing works
Huang, Y., Jiang, Z., & Wei, Y. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0034 · Cited by 9 · see citing works
Shimoda, M., Mashiko, A., Katakura, Y., Sanada, J., Fushimi, Y., Obata, A., Kimura, T., Kohara, K., Tatsumi, F., Nakanishi, S., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0161 · Cited by 7 · see citing works
An, J., Choi, H., Choi, J., Lim, H., Huh, W., Oh, Y., Park, J. S., Han, J., Lim, S. K., Lim, C., et al. (2024) · Veterinary Medicine and Science · doi:10.1002/vms3.1454 · Cited by 6 · see citing works
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6 · see citing works
Kurozumi, A., Okada, Y., & Tanaka, Y. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0577 · Cited by 5 · see citing works
Kamoshima, H., Nomoto, H., Yamashita, K., Takahashi, Y., Tsuchida, K., Kuwabara, S., Miya, A., Cho, K. Y., Kameda, H., Nakamura, A., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0573 · Cited by 5 · see citing works
Ghouri, N., Javed, H., & Sattar, N. A. (2020) · Current Diabetes Reviews · doi:10.2174/1573399817666201228120725 · Cited by 4 · see citing works
Li, Y., Li, H., Dong, L., Lin, D., Xu, L., Lou, P., Zang, D., Wang, K., & Ma, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923376 · Cited by 4 · see citing works
Saha, S., & Saha, S. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00544-x · Cited by 4 · see citing works
Najafipour, M., Najafipour, F., Ostadrahimi, A., Ghavami, M., Razaghi, Z., Tutunchi, H., & Alamdari, N. M. (2024) · Health Promotion Perspectives · doi:10.34172/hpp.42486 · Cited by 4 · see citing works
In silico studies for the identification of potential SGLT2 inhibitors
Bhupal, R., & Asati, V. (2022) · Pharmaspire · doi:10.56933/pharmaspire.2022.14218 · Cited by 3 · see citing works
Aldossari, B., & Aldossari, S. (2025) · International Medical Case Reports Journal · doi:10.2147/imcrj.s537615 · Cited by 2 · see citing works
Ogawa, S., Nako, K., & Ito, S. (2018) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.44 · Cited by 2 · see citing works
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies
Ma, J., Zhao, Y., Fan, H., & Liu, J. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.2 · Cited by 3 · see citing works
Saha, S., Saha, S., & Gayen, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01192-7 · Cited by 2 · see citing works
Mărgineanu, C., Usatiuc, L.-O., Sur, M. L., Similie, M., Bolunduț, A. C., Szabo, C.-E., Anton-Păduraru, D.-T., & Roman, G. (2026) · Children · doi:10.3390/children13060744 · Cited by 1 · see citing works
Madhu, S., & Raizada, N. (2023) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.379597 · Cited by 1 · see citing works
Morales, L. F. M., & Leal, J. P. M. (2019) · Revista Medica Sinergia · doi:10.31434/rms.v4i10.281 · Cited by 1 · see citing works
Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins
Krentz, A. J., Weyer, C., & Hompesch, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_3
Regulating Inflammatory Cytokines in the Diabetic Heart
Yadav, S. K., Kambis, T. N., & Mishra, P. K. (2019) · Springer eBooks · doi:10.1007/978-981-13-8273-4_19
Jermendy, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.9
Garnier, R., Mathieu-Huart, A., Ronga-Pezeret, S., Nouyrigat, E., Benoît, P., Goullé, J., Granon, C., Manel, J., Manouchehri, N., Nisse, P., et al. (2020) · Annales de Toxicologie Analytique · doi:10.1016/j.toxac.2020.05.004
Sodium Glucose Cotransporter Inhibitors for the Treatment of Diabetes
Jesus, A. R., Harrison, B. A., & Dore, T. M. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc277
Kitsios, K., & Trakatelli, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261486127
- Authors
- El Masri, D., Ghosh, S., & Jaber, L. A.
- Affiliations
- Wayne State University (US)
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Corresponding author
- Ghosh, Samiran
- Jaber, Linda A.
- ORCID
- Ghosh, Samiran
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 137
- Pages
- 83-92
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2782148351
- Cited by
- 45
- References
- 49
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 4 · 2021: 11 · 2020: 8 · 2019: 8 · 2018: 5
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Research and Clinical Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- SGLT2 inhibitors, type 1 diabetes, glycemic control, HbA1c, body weight, insulin dose, adverse events, insulin combination therapy, drug safety
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
